Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.
about
Importance of metabolic rate to the relationship between the number of genes in a functional category and body size in Peto's paradox for cancerFoot-and-mouth disease virus infection inhibits LGP2 protein expression to exaggerate inflammatory response and promote viral replication.The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications.Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune PathwaysTowards precision radiotherapy for use with immune checkpoint blockers.Crosstalk between Cytoplasmic RIG-I and STING Sensing Pathways.RIG-I: a multifunctional protein beyond a pattern recognition receptor.Mechanisms regulating immune surveillance of cellular stress in cancer.Suppression of Transposable Elements in Leukemic Stem Cells.Innate sensing of cancer's non-immunologic hallmarks.Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses.Host STING-dependent MDSC mobilization drives extrinsic radiation resistance.PARP1 depletion induces RIG-I-dependent signaling in human cancer cells.Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies.A GTPase-activating protein binding protein (G3BP1) / antiviral protein relay conveys arteriosclerotic Wnt signals in aortic smooth muscle cells.Effects of retinoic acid-inducible gene-I-like receptors activations and ionizing radiation cotreatment on cytotoxicity against human non-small cell lung cancer in vitro.Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment.The DNA damage response in immunotherapy and radiation
P2860
Q28598169-CBFC4ED1-F07B-49F4-AB90-270B46FF5935Q33815921-DA6A565C-8D81-484E-88D2-516CD191D494Q37518395-8749BBDB-649B-4056-8321-E3D94CC7B34FQ37690959-D78D62B1-2F48-4F40-8831-1034DF76F877Q38656599-8DC595BE-3CAD-4A5A-9DEE-289934BAA2B4Q39078459-FDF1F531-0D42-4ACC-A76D-22EC9FF8ED5FQ39358994-9CB90925-B1A8-441F-86AE-0797ADD6394FQ39458697-8654BFF6-C785-4E5F-B59C-75CD6C4934C8Q40098712-4631B8D2-D6EF-4BCC-AEE3-D1E9F3F187BDQ46065433-09BFA743-2876-4C72-BA03-93609A07A43BQ46189367-FE46D389-F760-4C38-92DA-819E31D6029FQ47614555-66B210AE-58C6-4250-8FF6-9D37A94659FFQ48245206-4C8D599D-9E5A-43AF-9718-FBF8E19D548CQ51758824-24447FF2-F4D5-4FEC-AD87-74399D06004CQ52568331-0D91B6F2-2B89-47C9-B14D-0FBE430571DBQ52601695-885FDA46-35DC-45B7-B847-5D021E413BCDQ55396166-ECB73D6A-99AD-4925-AD76-1DE31CA1096EQ55508841-64CC9CC7-81BD-47F2-8127-128B78AB61B8Q58119182-75C298F7-9692-4FD7-A288-5222CE378158
P2860
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.
@en
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.
@nl
type
label
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.
@en
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.
@nl
prefLabel
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.
@en
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.
@nl
P2093
P2860
P356
P1433
P1476
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.
@en
P2093
Akash D Parekh
Anthony C Wong
Diana Rose E Ranoa
Jonathan P Staley
Jorge Andrade
Nikolai N Khodarev
Sean P Pitroda
Shizuo Akira
Takashi Satoh
P2860
P304
26496-26515
P356
10.18632/ONCOTARGET.8420
P407
P577
2016-03-28T00:00:00Z